DGAP-News

Sangui BioTech International Inc.: SanguiBioTech yields revenues of over USD70,000 in Q1 2015 according to preliminary figures

DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter
Results
Sangui BioTech International Inc.: SanguiBioTech yields revenues of
over USD70,000 in Q1 2015 according to preliminary figures

07.10.2014 / 15:30

---------------------------------------------------------------------

SanguiBioTech yields revenues of over USD70,000 in Q1 2015 according to
preliminary figures

Witten, Germany, October 07, 2014 - According to preliminary, unaudited
figures Sangui Biotech International, Inc. yielded revenues from royalties
and product sales of more than USD70,000 in the course of the first quarter
of its financial year 2015, ended September 30, 2014. In the fourth quarter
of the 2014 financial year (ended June 30, 2014) revenues had amounted to
USD43,729; in the first quarter of its financial year 2014 (ended September
30, 2014) the company reported revenues of USD26,527.

Sangui Biotech International, Inc.,
Revenue Development for the 2013 thru 2015
Financial Years (per quarter)

Fin. Quarter           USD

2013 Q1                20.549

2013 Q2                27.494

2013 Q3                33.388

2013 Q4                24.056

2014 Q1                26.527

2014 Q2                33.776

2014 Q3                29.438

2014 Q4                43.729

2015 Q1 (p)            >70.000

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]
Some of the statements contained in this news release discuss future
expectations, contain projections of results of operation or financial
condition or state other "forward-looking" information. These statements
are subject to known and unknown risks, uncertainties, and other factors
that could cause the actual results to differ materially from those
contemplated by the statements. The forward-looking information is based on
various factors and is derived using numerous assumptions. Important
factors that may cause actual results to differ from projections include,
among many others, the ability of the Company to raise sufficient capital
to meet operating requirements. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," and variations of
such words and similar expressions are intended to identify such
forward-looking statements. Unless required by law, the Company undertakes
no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise.



---------------------------------------------------------------------

07.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


290530 07.10.2014